Dear Ms. Mills:

Please refer to your supplemental new drug application dated June 12, 2006, received June 14, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Serostim (somatropin [rDNA origin] for injection).

We acknowledge receipt of your submissions dated September 28, 2006, and February 6 and 27, March 27, April 9 and 24, 2007.

This supplemental new drug application provides for the revision of the CLINICAL PHARMACOLOGY, CLINICAL STUDIES, PRECAUTIONS, and ADVERSE REACTIONS sections of the package insert to include information regarding use in patients with HIV-associated adipose redistribution syndrome (HARS).

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the attached agreed-upon labeling text).

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit either an electronic version or 20 paper copies of the FPL as soon as it is available (no more than 30 days after it is printed). If paper copies are submitted, individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 20-604/S-040.” Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.
In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Metabolism and Endocrinology Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
5515 Security Lane  
HFD-001, Suite 5100  
Rockville, MD 20852

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, MD  
Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure: Package Insert
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Eric Colman
7/13/2007 11:17:33 AM
Eric Colman for Mary Parks